CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Sling catches $123M series C for thyroid eye disease pill

Positive
AI Analysis

Summary

Sling Therapeutics raised $123M in Series C funding to advance the first late-stage oral drug for thyroid eye disease, positioning it to compete with Amgen and Viridian Therapeutics if approved.

Importance:6/10
Sentiment:
0.70
fundingSeries Cthyroid eye diseaseoral druglate-stage
Related Companies

Read the original article

Published by BioSpace on September 16, 2026 12:30 PM

Read Original